Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Eye Test May Offer Early Diagnosis for Alzheimer’s

A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.

Read More »

Major study debunks healthy moderate drinking myth

Blood pressure and stroke risk rise steadily the more alcohol people drink, and previous claims that one or two drinks a day might protect against stroke are not true, according to a genetic study.

Read More »

NIH Begins Trial of Potential Universal Flu Vaccine

Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.

Read More »

ViiV Healthcare Announces 3-Year HIV Data for Juluca 2-Drug Combo

ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.

Read More »

Exclusive: Astellas’ Xospata Provides Strong OS Benefits in Phase III Trial

Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.

Read More »

AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.

Read More »

Shares in Galapagos jump after arthritis drug results

Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.

Read More »

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.

Read More »

Aldeyra’s eye drug meets main goal in late-stage study

Aldeyra Therapeutics Inc.’s drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

Read More »

Conatus Pharma Stock Craters After 3rd Failed NASH Trial

In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom